Burden of Crohn’s disease: economics and quality of life aspects in Italy

References

• AchkarJPBarmadaMMDuerrRHPerinuclear neutrophil antibodies are not markers for genetic susceptibility or indicators of genetic heterogeneity in familial ulcerative colitisAm J Gastroenterol2002972343234912358254
   PubMed Web of Science ®Google Scholar
• LashnerBAColorectal cancer surveillance for patients with inflammatory bowel diseaseGastrointest Endosc Clin N Am20021213514311916156
   PubMedGoogle Scholar
• WolfJMLashnerBAInflammatory bowel disease: sorting out the optionsCleve Clinic J Med200269621631
   PubMed Web of Science ®Google Scholar
• MattarMCLoughDPishvaianMJCharabatyACurrent management of inflammatory bowel disease and colorectal cancerGastrointest Cancer Res20114536121673876
   PubMedGoogle Scholar
• PeuraDFennertyBLashnerBOsteoporosis for the GastroenterologistHertfordshire, UKStrategic Consultants International2002
   Google Scholar
• LucioniCLa qualità della vita nella valutazione economicaCronache Farmaceutiche, AnnoXXXVII61994 Italian
   Google Scholar
• HodgsonTThe state of the art of cost of illness estimatesAdv Health Econ Health Serv Res1983412916410265653
   PubMedGoogle Scholar
• DrummondMFO’BrienBJStoddartGLMethods for the Economic Evaluation of Health Care Programmes3rd edNew York, NYOxford University Press2006
   Google Scholar
• BlomqvistPEkbomAInflammatory bowel diseases: health care and costs in Sweden in 1994Scand J Gastroenterol199732113411399399395
   PubMed Web of Science ®Google Scholar
• BernsteinCNPapineauNZajaczkowkiJDirect hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospitalAm J Gastroenterol20009567768310710056
   PubMed Web of Science ®Google Scholar
• CohenRDLarsonLRRothJMBeckerRVMummertLLThe cost of hospitalization in Crohn’s diseaseAm J Gastroenterol20009552453010685762
   PubMed Web of Science ®Google Scholar
• SilversteinDLoftusEVSandbornWJClinical course and costs of care for Chron’s disease: Markov model analysis of a population-based cohortGastroenterology1999117495710381909
   PubMed Web of Science ®Google Scholar
• FeaganBGReview article: economic issues in Crohn’s disease – assessing the effects of new treatments on health-related quality of lifeAliment Pharmacol Ther199913 Suppl 4293710597337
   PubMed Web of Science ®Google Scholar
• BorgaonkarMRIrvineJRQuality of life measurement in gastrointestinal and liver disordersGut20004744445410940286
   PubMed Web of Science ®Google Scholar
• LichtensteinGRBalaMHanCDeWoodyKSchaibleTInfliximab improves quality of life in patients with Crohn’s diseaseInflamm Bowel Dis2002823724312131606
   PubMed Web of Science ®Google Scholar
• Italian Health Economics AssociationGuidelines proposal on how to conduct economic evaluation studies of health programsPharmacoeconomics – Italian Research Articles2009118393 Italian
   Google Scholar
• Health Ministry, DRG TariffTUC Tariffa Unica Convenzionale, Conferenza delle Regioni e delle Province Autonome, compensazione interregionale della mobilità sanitaria Testo Unico, Versione in vigore per le attività dell’anno 2010RomeMay 5, 2011 Italian
   Google Scholar
• Health Ministry2010National Tariff NomenclatorNomenclatore delle Prestazioni di assistenza specialistica ambulatorialeMinistero della Salute2011 Italian
   Google Scholar
• Italian Medicines AgencyNegoziazione e rimborsabilità Italian. Available from: http://www.agenziafarmaco.gov.it/it/content/negoziazione-e-rimborsabilit%C3%A0Accessed September 23, 2011
   Google Scholar
• Banca d’ItaliaLa ricchezza delle famiglie italiane – anno 2010 n. 64-2011 14-12-2011. Italian. Available from: http://www.bancaditalia.it/statistiche/stat_mon_cred_finAccessed April 21, 2012
   Google Scholar
• ISTAT Istituto Nazionale di StatisticaNation Institute of Statistics Italian. Available from: http://seriestoriche.istat.it/index.php?id=7&user_100ind_pi1[id_pagina]=70&cHash=468e508f3b1982a1c919b740b8f13d66Accessed April 21, 2012
   Google Scholar
• EQ-5D™ [homepage on the Internet]Rotterdam, The NetherlandsEuroQol Group Available from: http://www.euroqol.orgAccessed April 21, 2012
   Google Scholar
• [No authors listed]EuroQoL: a new facility for the measurement of health-related quality of lifeHealth Policy19901619920810109801
   PubMed Web of Science ®Google Scholar
• Essink-BotMLStouthardMEBonselGJGeneralizability of valuations on health states collected with the EuroQolc-questionnaireHealth Econ199322372468275169
   PubMedGoogle Scholar
• BrooksREuroQol: the current state of playHealth Policy199637537210158943
   PubMed Web of Science ®Google Scholar
• KindPThe EuroQol instrument: an index of health-related quality of lifeSpikerBQuality of Life and Pharmacoeconomics in Clinical Trials2nd edPhiladelphia, PALippincott-Raven Publishers1996
   Google Scholar
• DolanPGudexCKindPA Social Tariff for EuroQol: Results from a UK General Population Survey Discussion Paper 138New York, NYCentre of Health Economics, University of York1995
   Google Scholar
• FeaganBGVreelandMGLarsonLRAnnual cost of care for Crohn’s disease: a payor prospectiveAm J Gastroenterol2000951955196010950042
   PubMed Web of Science ®Google Scholar
• LucioniCGaranciniMPMassi-BenedettiMMazziSSerraGThe costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-studyTreat Endocrinol2003212113315871548
   PubMedGoogle Scholar
• BodgerKKikuchiTHughesDCost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost dataAliment Pharmacol Ther20093026527419438428
   PubMed Web of Science ®Google Scholar
• DretzkeJEdlinRRoundJA systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn’s diseaseHealth Technol Assess201115124421291629
   PubMed Web of Science ®Google Scholar
• BinionDGLouisEOldenburgBEffect of adalimumab on work productivity and indirect costs in moderate to severe Crohn’s disease: a meta-analysisCan J Gastroenterol20112549249621912760
   PubMed Web of Science ®Google Scholar
• YuAPJohnsonSWangSTCost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn’s diseasePharmacoeconomics20092760962119663531
   PubMed Web of Science ®Google Scholar
• LoomesDETeshimaCJacobsPFedorakRNHealth care resource use and costs in Crohn’s disease before and after infliximab therapyCan J Gastroenterol20112549750221912761
   PubMed Web of Science ®Google Scholar
• SprakesMBFordACSuaresNCCosts of care for Crohn’s disease following the introduction of infliximab: a single-centre UK experienceAliment Pharmacol Ther2010321357136321050238
   PubMed Web of Science ®Google Scholar
• KoopmanshapMACost of illness studies: useful for health policy?Pharmacoeconomics199814143148
   Web of Science ®Google Scholar